{"product_id":"prevention-of-type-2-diabetes-hardback-9780470857335","title":"Prevention of Type 2 Diabetes (Hardback) 9780470857335","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003ePrevention of Type 2 Diabetes\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eManfred Ganz (Edited by), M Ganz (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470857335, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 7 January 2005\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e384 pages\u003cbr\u003e25.2 x 17.4 x 2.7 cm, 0.85 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"…enjoyable and easy to read…a worthy library addition…\" (\u003ci\u003eThe Annals of Pharmacotherapy\u003c\/i\u003e, September 2005)  \u003cp\u003e\"…presents the latest global perspective on the affliction.\" (\u003ci\u003eElectric Review\u003c\/i\u003e, April\/May 2005)\u003c\/p\u003e \u003cp\u003e\"This is a timely and helpful treatment of an important public health topic. I am unaware of any other contemporary books which address exactly this issue.\" (\u003ci\u003eDoody's Health Services\u003c\/i\u003e)\u003c\/p\u003e \u003cp\u003e\"An ambitious title, written by some of the world’s leading diabetologists, it takes a very careful approach …\" \u003ci\u003e(Pediatric Endocrinology Reviews (PER), Vol. 3: September 2005)\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\" … an excellent resource for professionals … a one-stop source for understanding the state of current prevention knowledge about type 2 diabetes.\" (\u003ci\u003eDiabetes Technology \u0026amp; Therapeutics\u003c\/i\u003e, August 2006) \u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThis book  provides a unique and comprehensive synopsis of the prevention and early diagnosis of Type 2 Diabetes. It features articles by key opinion leaders in diabetes from North America, Europe and the Asia-Pacific region who describe the gravity of the problem and the important issue of screening, including contributions on the perspectives of the International Diabetes Federation and the World Health Organization.  \u003cp\u003eOnce patients at risk have been identified, the key issue is to prevent their progression to full-blown diabetes. Several chapters address this, particularly the difficult task of changing people’s behaviour. Prevention of the complications associated with diabetes involves more targeted interventions, which are discussed by experts in the relevant areas.\u003c\/p\u003e \u003cp\u003eThis book offers both a global perspective and local solutions. Key contributors include Paul Zimmet and Pierre Lefèbvre, President of the International Diabetes Federation who has written a chapter and a foreword.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePraise from the reviews:\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\"[A]n excellent resource for professionals who want a good means for getting up to speed on the prevention angle. It is all-inclusive from many perspectives – authorship of chapters, rich reference lists, and content (…). This book is a one-stop source for understanding the state of current prevention knowledge about type 2 diabetes.\"\u003cbr\u003e—\u003cb\u003eDIABETES TECHNOLOGY \u0026amp; THERAPEUTICS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\"This is a timely and helpful treatment of an important public health topic. I am unaware of any other contemporary books which address exactly this issue.\"\u003cbr\u003e—\u003cb\u003eDOODY'S HEALTH SERVICES\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\"An ambitious title, written by some of the world’s leading diabetologists, it takes a very careful approach ( …)\"\u003cbr\u003e—\u003cb\u003ePEDIATRIC ENDOCRINOLOGY REVIEWS (PER)\u003c\/b\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eForeword xiii\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003eList of Contributors xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 The Diabetes Epidemic: Description of the Problem 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Diabetes Epidemic; Genes and Environment Clashing 3\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePaul Zimmet, Adrian Cameron and Jonathan Shaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 3\u003c\/p\u003e \u003cp\u003eAn Epidemiological Perspective 3\u003c\/p\u003e \u003cp\u003eThe Hidden Epidemic – Impaired Glucose Tolerance and Impaired Fasting Glycaemia 6\u003c\/p\u003e \u003cp\u003eGlucose Intolerance and the Metabolic Syndrome 6\u003c\/p\u003e \u003cp\u003eGlobalization – its Impact on Human Health 8\u003c\/p\u003e \u003cp\u003eType 2 Diabetes in Children and Adolescents 9\u003c\/p\u003e \u003cp\u003ePrevention – the Reality and the Challenge 10\u003c\/p\u003e \u003cp\u003eReferences 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Type 2 Diabetes Mellitus: Primary and Secondary Prevention The Vision of the International Diabetes Federation 15\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePierre Lefèbvre\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 15\u003c\/p\u003e \u003cp\u003ePrimary Prevention of Type 2 Diabetes Mellitus 16\u003c\/p\u003e \u003cp\u003ePrevention of Complications of Type 2 Diabetes Mellitus 17\u003c\/p\u003e \u003cp\u003eThe Global Issue 18\u003c\/p\u003e \u003cp\u003eReferences 19\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Type 2 Diabetes Mellitus in Children and Adolescents 21\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas Reinehr and Martin Wabitsch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 21\u003c\/p\u003e \u003cp\u003ePathophysiology of Type 2 Diabetes Mellitus in Children and Adolescents 22\u003c\/p\u003e \u003cp\u003eEpidemiology of Type 2 Diabetes Mellitus in Children and Adolescents 23\u003c\/p\u003e \u003cp\u003eClinical Presentation of Type 2 Diabetes Mellitus in Children and Adolescents 25\u003c\/p\u003e \u003cp\u003eClinical Features of Caucasian Children with Type 2 Diabetes Mellitus 25\u003c\/p\u003e \u003cp\u003eDifferential Diagnosis of Type 2 Diabetes Mellitus in Children and Adolescents 27\u003c\/p\u003e \u003cp\u003eDiagnostic criteria of Type 2 Diabetes Mellitus in Children and Adolescents 29\u003c\/p\u003e \u003cp\u003eComplications of Type 2 Diabetes Mellitus in Children and Adolescents 31\u003c\/p\u003e \u003cp\u003eScreening for Type 2 Diabetes Mellitus in Children and Adolescents 33\u003c\/p\u003e \u003cp\u003eTreatment of Type 2 Diabetes Mellitus in Children and Adolescents 34\u003c\/p\u003e \u003cp\u003ePharmacological Treatment of Type 2 Diabetes Mellitus in Children and Adolescents 35\u003c\/p\u003e \u003cp\u003eMonitoring and Treatment of Complications of Type 2 Diabetes Mellitus in Children and Adolescents 37\u003c\/p\u003e \u003cp\u003ePrevention of Type 2 Diabetes Mellitus in Children and Adolescents 37\u003c\/p\u003e \u003cp\u003eConclusions 38\u003c\/p\u003e \u003cp\u003eReferences 38\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Screening for Type 2 Diabetes 41\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Screening for Undiagnosed Diabetes: Whom, Where, When and How 43\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTim Kenealy, Bruce Arroll and Peter Müller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eUndiagnosed Diabetes and Its Harms 43\u003c\/p\u003e \u003cp\u003eThe Rate of Undiagnosed Diabetes in New Zealand 43\u003c\/p\u003e \u003cp\u003eShould We Screen for Diabetes? 45\u003c\/p\u003e \u003cp\u003eTheory of Screening 48\u003c\/p\u003e \u003cp\u003eScreening Theories are Difficult to Apply to Diabetes: Implications of the Diagnostic Criteria for Screening Decisions 55\u003c\/p\u003e \u003cp\u003eCurrent Recommendations, New Zealand and International 56\u003c\/p\u003e \u003cp\u003eCurrent Practice in New Zealand 56\u003c\/p\u003e \u003cp\u003eStudies of Practical Screening in New Zealand 57\u003c\/p\u003e \u003cp\u003eSystematic Opportunistic Screening in General Practice 58\u003c\/p\u003e \u003cp\u003eWho to Test: Which Groups are at Relatively High Risk? 59\u003c\/p\u003e \u003cp\u003eHow to Test: Specific Screening Tests and cut-off Values? 62\u003c\/p\u003e \u003cp\u003eScreening Intervals 71\u003c\/p\u003e \u003cp\u003eDifficulty Applying Recommendations to Individual Patients 71\u003c\/p\u003e \u003cp\u003eScreening Algorithms for Asymptomatic People 72\u003c\/p\u003e \u003cp\u003eSummary 72\u003c\/p\u003e \u003cp\u003eReferences 73\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Genetic Screening and Prevention of Type 2 Diabetes 81\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePaolo Pozzilli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 81\u003c\/p\u003e \u003cp\u003eLessons from Type 1 Diabetes for Genetic Screening 83\u003c\/p\u003e \u003cp\u003eMethods for Early Prediction of Type 1 Diabetes and Prevention Strategies 84\u003c\/p\u003e \u003cp\u003eType 2 Diabetes: Where do We Stand as regards Genetic Screening 85\u003c\/p\u003e \u003cp\u003eGenes that are Identified with a Predisposition to Type 2 Diabetes: the New Scene 86\u003c\/p\u003e \u003cp\u003eHow can We Track the Prediabetes Period using Genetic Markers? 87\u003c\/p\u003e \u003cp\u003eGenetic Screening for MODY and Potential Preventive Strategy 88\u003c\/p\u003e \u003cp\u003eConclusion 90\u003c\/p\u003e \u003cp\u003eAcknowledgements 91\u003c\/p\u003e \u003cp\u003eReferences 91\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Screening Parameters and Techniques: Limitations and Opportunities 93\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKnut Borch-Johnsen and Charlotte Glümer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe Epidemiology of Type 2 Diabetes 94\u003c\/p\u003e \u003cp\u003eWhat is Screening and How do We Evaluate a Screening Test? 95\u003c\/p\u003e \u003cp\u003eScreening Strategies 96\u003c\/p\u003e \u003cp\u003eWho Should be Screened – Targeted Screening Strategies Based on Phenotypical Characteristics? 99\u003c\/p\u003e \u003cp\u003eLimitations, Perspectives and Recommendation 99\u003c\/p\u003e \u003cp\u003eReferences 101\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Screening for Diabetes Mellitus – the World Health Organization Perspective 105\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGojka Roglic, Rhys Williams and Stephen Colagiuri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 105\u003c\/p\u003e \u003cp\u003eFormulating Policies on Screening for Type 2 Diabetes 109\u003c\/p\u003e \u003cp\u003eWidening the Evidence Base 112\u003c\/p\u003e \u003cp\u003eImplementing Policies on Screening for Type 2 Diabetes 117\u003c\/p\u003e \u003cp\u003eConclusions and Recommendations 117\u003c\/p\u003e \u003cp\u003eReferences 120\u003c\/p\u003e \u003cp\u003eSection 3 Prevention of Type 2 Diabetes 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Findings from Preventive Type 2 Diabetes Trials 127\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMarkolf Hanefeld\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe ‘Common Soil’ Hypothesis – a Rationale for Preventive Measures in Subjects with IGT 128\u003c\/p\u003e \u003cp\u003eLifestyle Trials with Prevention of Diabetes as Primary Objective 130\u003c\/p\u003e \u003cp\u003ePharmacological Trials with Prevention of Diabetes as Primary Objective 132\u003c\/p\u003e \u003cp\u003eCoronary Heart Disease Prevention Trials with Prevention of Diabetes as the Secondary Objective 138\u003c\/p\u003e \u003cp\u003eStudies for Primary Prevention of Diabetes in Progress 140\u003c\/p\u003e \u003cp\u003eIs Impaired Glucose Tolerance (IGT) a Disease? 142\u003c\/p\u003e \u003cp\u003eWho Should be Treated (and How)? 145\u003c\/p\u003e \u003cp\u003eDo We Treat Type 2 Diabetes too Late? 146\u003c\/p\u003e \u003cp\u003eReferences 147\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 A Paradigm Shift is Needed in the Primary Prevention of Type 2 Diabetes 153\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJaakko Tuomilehto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePrimary Prevention of Type 2 Diabetes – the Current Paradigm 153\u003c\/p\u003e \u003cp\u003eRe-Defining the Paradigm of Primary Prevention of Type 2 Diabetes 155\u003c\/p\u003e \u003cp\u003eNew Paradigm – A Population Approach for Prevention of Type 2 Diabetes 155\u003c\/p\u003e \u003cp\u003eNew Paradigm – Who is at High Risk? 156\u003c\/p\u003e \u003cp\u003eNew Paradigm – True Primary Prevention: Targeting People Before Their Blood Glucose Values are Abnormal 158\u003c\/p\u003e \u003cp\u003eNew Paradigm – Prevention of Complications of Type 2 Diabetes by Preventing Type 2 Diabetes Itself 159\u003c\/p\u003e \u003cp\u003eNew Paradigm – How could Money for Diabetes Care be Allocated in a More Efficient Way? 161\u003c\/p\u003e \u003cp\u003eComment 162\u003c\/p\u003e \u003cp\u003eReferences 165\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 The Behaviour Change Process 169\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFrank J. Snoek and Richard R. Rubin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 169\u003c\/p\u003e \u003cp\u003eReadiness to Change 170\u003c\/p\u003e \u003cp\u003eGoal Setting 172\u003c\/p\u003e \u003cp\u003eSupporting Behaviour Change 172\u003c\/p\u003e \u003cp\u003eChanges and Maintenance 173\u003c\/p\u003e \u003cp\u003eImplications 175\u003c\/p\u003e \u003cp\u003eReferences 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4 Prevention of Complications Of Type 2 Diabetes 179\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Preventive Disease Management – Risk Stratification as a New Tool in the Hands of General Practitioners 181\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas Konrad\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChronic Diseases, Health-Care Systems, Internet and Economic Burden: From Intervention to Prevention 181\u003c\/p\u003e \u003cp\u003eBasics of Preventive Medicine: Risk Stratification, Genetic Testing and Information 183\u003c\/p\u003e \u003cp\u003ePrinciples of Assessment of Risk Factors in Clinical Practice for Cardiovascular Diseases and Diabetes Mellitus Type 2: Consequences for the Individual Life 185\u003c\/p\u003e \u003cp\u003ePreventive Disease Management for Diabetes Mellitus Type 2 and Cardiovascular Diseases: Phenotyping – the Early Detection of Insulin Resistance and Endothelial Dysfunction 189\u003c\/p\u003e \u003cp\u003eIntegrative Preventive Care: Community-Based Strategy to Avoid Chronic Diseases 193\u003c\/p\u003e \u003cp\u003eSummary 197\u003c\/p\u003e \u003cp\u003eReferences 198\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Prevention of Obesity and Lipid Disorders 203\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eHermann Liebermeister\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReasons for Prevention 203\u003c\/p\u003e \u003cp\u003eProblems in Prevention 212\u003c\/p\u003e \u003cp\u003eCommunity-Based Prevention Studies 216\u003c\/p\u003e \u003cp\u003ePromoting Physical Activity 218\u003c\/p\u003e \u003cp\u003eWorkside Interventions in Adults 220\u003c\/p\u003e \u003cp\u003eSpecific Weight Gain Prevention Trials in Adults 220\u003c\/p\u003e \u003cp\u003ePrevention of Diabetes and Obesity 222\u003c\/p\u003e \u003cp\u003ePrevention of Lipid Disorders 227\u003c\/p\u003e \u003cp\u003ePerspectives of Obesity and Dyslipidaemia Prevention 230\u003c\/p\u003e \u003cp\u003eAcknowledgement 234\u003c\/p\u003e \u003cp\u003eReferences 235\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Renal Dysfunction and Hypertension, Focus on Type 2 Diabetes 245\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCarl Erik Mogensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 245\u003c\/p\u003e \u003cp\u003eHistorical Aspects 246\u003c\/p\u003e \u003cp\u003eEvaluation of Diabetic Renal Disease and Classification 246\u003c\/p\u003e \u003cp\u003eDiagnostic Procedures 249\u003c\/p\u003e \u003cp\u003ePrevention 251\u003c\/p\u003e \u003cp\u003eTreatment Strategy 252\u003c\/p\u003e \u003cp\u003eTreatment in Overt Diabetic Renal Disease 255\u003c\/p\u003e \u003cp\u003eRecent Treatment Guidelines for Patients with Diabetes Mellitus with Focus on Hypertension 257\u003c\/p\u003e \u003cp\u003eThe Dual- or Triple- Jeopardy Concept 257\u003c\/p\u003e \u003cp\u003eGoals for Blood Pressure 258\u003c\/p\u003e \u003cp\u003eOld and Very New Guidelines 258\u003c\/p\u003e \u003cp\u003eScreening for Microalbuminuria 259\u003c\/p\u003e \u003cp\u003ePrevention and Intervention Related to Type 2 Diabetes 261\u003c\/p\u003e \u003cp\u003eSummary 263\u003c\/p\u003e \u003cp\u003eReferences 263\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Diabetic Retinopathy in the 21st Century: Screening and Visual Outcomes 271\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAyad Al-Bermani and Roy Taylor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 271\u003c\/p\u003e \u003cp\u003eEpidemiology 272\u003c\/p\u003e \u003cp\u003eGood Glycaemic Control 272\u003c\/p\u003e \u003cp\u003eGood Blood Pressure Control 272\u003c\/p\u003e \u003cp\u003eOther Risk Factors 273\u003c\/p\u003e \u003cp\u003eScreening 273\u003c\/p\u003e \u003cp\u003eEffect of Screening Upon Rates of Blindness 277\u003c\/p\u003e \u003cp\u003eTreatment of Diabetic Retinopathy 278\u003c\/p\u003e \u003cp\u003ePanretinal Photocoagulation 278\u003c\/p\u003e \u003cp\u003eTreatment of Macular Oedema 280\u003c\/p\u003e \u003cp\u003eVitrectomy 280\u003c\/p\u003e \u003cp\u003eSummary 282\u003c\/p\u003e \u003cp\u003eReferences 282\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Prevention and Treatment of Diabetic Neuropathy 285\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAnders A. F. Sima\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 285\u003c\/p\u003e \u003cp\u003eClinical Presentation and Classification of DPN 286\u003c\/p\u003e \u003cp\u003ePathogenetic Mechanisms 288\u003c\/p\u003e \u003cp\u003eTested Therapies 292\u003c\/p\u003e \u003cp\u003eFuture Therapeutic Opportunities 296\u003c\/p\u003e \u003cp\u003eConcluding Thoughts 300\u003c\/p\u003e \u003cp\u003eReferences 301\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 The Cardiologist’s View: Prevention of Macrovascular Complications 313\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael Faust, Sabine Wiedenmann and Reinhard Griebenow\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePrevalence of Cardiovascular Complications in Patients with Diabetes Mellitus 313\u003c\/p\u003e \u003cp\u003eOccurrence of Diabetes in Patients with Cardiovascular Disease 315\u003c\/p\u003e \u003cp\u003ePrognosis and Course of Coronary Heart Disease in Diabetic Patients 315\u003c\/p\u003e \u003cp\u003eExplanatory Models for the Particular Fatal Course of Coronary Heart Disease in Diabetic Patients (Risk Factors) 316\u003c\/p\u003e \u003cp\u003eCardiovascular Complications – Preventive and Therapeutic Options 317\u003c\/p\u003e \u003cp\u003eInterventional Revascularization 319\u003c\/p\u003e \u003cp\u003eProcedure in Critical Ischaemia 320\u003c\/p\u003e \u003cp\u003eReferences 320\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Milestones and New Perspectives in Prevention of Type 2\u003cbr\u003e\u003c\/b\u003eDiabetes and its Complications 325\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCarl Erik Mogensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eClassification of Diabetes 325\u003c\/p\u003e \u003cp\u003eInsulin Treatment with Focus on Euglycemia in Type 2 Diabetic Patients 327\u003c\/p\u003e \u003cp\u003eSulphonylurea (SU) Preparations 329\u003c\/p\u003e \u003cp\u003eMetformin 330\u003c\/p\u003e \u003cp\u003eGlitazones 330\u003c\/p\u003e \u003cp\u003eThe Metabolic Syndrome 331\u003c\/p\u003e \u003cp\u003eHome Monitoring of Blood Glucose 331\u003c\/p\u003e \u003cp\u003eGlycated Haemoglobin 332\u003c\/p\u003e \u003cp\u003eDiabetes Nurses, ‘Diabetes School’ and Dietary Help 332\u003c\/p\u003e \u003cp\u003eLaser Treatment of Retinopathy, including Maculopathy, in Type 2 Diabetes 333\u003c\/p\u003e \u003cp\u003eDiabetic Foot Care and Related Neuropathy 333\u003c\/p\u003e \u003cp\u003eHigh Blood Pressure: Blood Pressure Lowering and Microalbuminuria 333\u003c\/p\u003e \u003cp\u003eLipid-Lowering Agents; Focus on Type 2 Diabetes 335\u003c\/p\u003e \u003cp\u003eThe Diet of Diabetic Patients 336\u003c\/p\u003e \u003cp\u003eMulti-Factorial Intervention with Treatment Goals 336\u003c\/p\u003e \u003cp\u003eNeuropathy 336\u003c\/p\u003e \u003cp\u003eConclusion 337\u003c\/p\u003e \u003cp\u003eReferences 338\u003c\/p\u003e \u003cp\u003eIndex 343\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Family \u0026amp; health [\u003ca title=\"See our other books on Family \u0026amp; health\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Family%20\u0026amp;%20health%20%5BVF%5D%22\"\u003eVF\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52278040494360,"sku":"9780470857335","price":115.89,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470857335.jpg?v=1781457423","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/prevention-of-type-2-diabetes-hardback-9780470857335","provider":"Freshly Printed Books","version":"1.0","type":"link"}